A Pollack

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610
    A Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1238-48. 2003
  2. ncbi request reprint Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:19-23. 2003
  3. ncbi request reprint Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    World J Urol 21:200-8. 2003
  4. ncbi request reprint Prostate cancer radiotherapy dose response: an update of the fox chase experience
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 171:1132-6. 2004
  5. ncbi request reprint Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 54:677-85. 2002
  6. ncbi request reprint Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:22-30; discussion 30-1. 2002
  7. ncbi request reprint Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02
    A Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 22:2133-40. 2004
  8. ncbi request reprint Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
    Alan Pollack
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 53:1097-105. 2002
  9. ncbi request reprint Lack of prostate cancer radiosensitization by androgen deprivation
    A Pollack
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 51:1002-7. 2001
  10. ncbi request reprint Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:337-49, x. 2003

Research Grants

  1. Xenogen IVIS-200 Bioluminescent Imaging System
    Alan Pollack; Fiscal Year: 2007

Collaborators

Detail Information

Publications78

  1. ncbi request reprint Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610
    A Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1238-48. 2003
    ..The protocol treatment randomization was RT alone versus RT plus short-course (approximately 4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB)...
  2. ncbi request reprint Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:19-23. 2003
    ..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
  3. ncbi request reprint Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    World J Urol 21:200-8. 2003
    ..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
  4. ncbi request reprint Prostate cancer radiotherapy dose response: an update of the fox chase experience
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 171:1132-6. 2004
    ....
  5. ncbi request reprint Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 54:677-85. 2002
    ..These issues were investigated in a cohort of men with Stage T1-T3 prostate cancer who were randomized to receive between 70 Gy and 78 Gy and were prospectively biopsied at about 2 years after the completion of radiotherapy (RT)...
  6. ncbi request reprint Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:22-30; discussion 30-1. 2002
    ..The results with long-term ADT are much more convincing than short-term ADT, and, as a consequence, 2 to 3 years are recommended...
  7. ncbi request reprint Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02
    A Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 22:2133-40. 2004
    ....
  8. ncbi request reprint Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
    Alan Pollack
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 53:1097-105. 2002
    ..A randomized radiotherapy dose escalation trial was undertaken between 1993 and 1998 to compare the efficacy of 70 vs. 78 Gy in controlling prostate cancer...
  9. ncbi request reprint Lack of prostate cancer radiosensitization by androgen deprivation
    A Pollack
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 51:1002-7. 2001
    ..Animal model studies have provided suggestive evidence that AD sensitizes cells to radiation, but this mechanism is difficult to confirm conclusively in vivo. This question was investigated in LNCaP cells grown in vitro...
  10. ncbi request reprint Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:337-49, x. 2003
    ..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
  11. ncbi request reprint Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT
    L Wang
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 5:29-41. 2004
    ..78). In conclusion, the use of the mMLC for IMRT of the prostate resulted in significant improvement in the DVH parameters of the prostate and critical organs, which may improve the therapeutic ratio...
  12. ncbi request reprint Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
    A Pollack
    Departments of Radiation Oncology, Biostatistics, Urology, and Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:3904-11. 2000
    ..To determine the effect of radiotherapy dose on prostate cancer patient outcome and biopsy positivity in a phase III trial...
  13. ncbi request reprint Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer
    G K Zagars
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 58:233-9. 2001
    ..The addition of prostatic radiation to ablation resulted in substantial and significant improvement in disease control and patient survival...
  14. ncbi request reprint Dosimetric evaluation of MRI-based treatment planning for prostate cancer
    L Chen
    Radiation Oncology Department, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Phys Med Biol 49:5157-70. 2004
    ..The difference in the target dose between CT- and MRI-based plans using homogeneous geometry was within 2.5%. Our results suggest that MRI-based treatment planning is suitable for radiotherapy of prostate cancer...
  15. ncbi request reprint External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era
    A Pollack
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 48:507-12. 2000
    ..To characterize the relationship of radiotherapy dose to prostate cancer patient outcome, with an emphasis on the influence of pretreatment prognostic variables...
  16. ncbi request reprint Clinical implementation of intensity-modulated tangential beam irradiation for breast cancer
    J S Li
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Med Phys 31:1023-31. 2004
    ..The IMRT technique has been proven practical for breast treatment clinically. The results showed that tangential IMRT improved the dose homogeneity in the breast and reduced the dose to the lung and heart...
  17. ncbi request reprint Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation
    P J Colletier
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 48:1507-12. 2000
    ..The objective was to determine if this vector sensitizes cells to radiation independently of their p53 status...
  18. ncbi request reprint Daily target localization for prostate patients based on 3D image correlation
    K Paskalev
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Phys Med Biol 49:931-9. 2004
    ..The impact of image noise on the performance of the algorithm has been tested. The results show that the algorithm accurately adjusts for target positional changes even with Gaussian noise levels as high as 20% inserted...
  19. ncbi request reprint Treatment planning using a dose-volume feasibility search algorithm
    G Starkschall
    Department of Radiation Physics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 49:1419-27. 2001
    ..In contrast to a search for the "best" plan, this approach can quickly determine feasibility and point out the most restrictive of the predetermined constraints...
  20. ncbi request reprint Simultaneous estimation of T(G2+M), T(S), and T(pot) using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometry
    R A White
    Department of Biomathematics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cytometry 41:1-8. 2000
    ..Inspection of the measured dynamic quantities, relative movement [RM(t)], fractions of labeled divided and undivided cells (f(lu)(t) and f(ld)(t)) suggests that T(G2+M), T(S), and T(pot) can be determined simultaneously...
  21. ncbi request reprint Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer
    N Taylor
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 56:755-63. 2003
    ..The optimal role of radiotherapy (RT) to the prostate bed after radical prostatectomy (RP) is the subject of much debate. In this study, the results of adjuvant RT (ART) and salvage RT (SRT) were compared...
  22. ncbi request reprint Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution
    P W Pisters
    Sarcoma Center, The University of Texas M D Anderson Cancer Center, Houston 77030 4195, USA
    J Clin Oncol 15:3481-7. 1997
    ..To review a single institution's long-term results with doxorubicin-based preoperative chemotherapy for American Joint Committee on Cancer (AJCC) stage IIIB extremity soft tissue sarcoma (STS)...
  23. ncbi request reprint Radiotherapy for stage II testicular seminoma
    G K Zagars
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 51:643-9. 2001
    ..CONCLUSIONS: PLSCI significantly diminishes the likelihood of relapse for Stage IIA, IIB, and IIC seminoma (mass <or=10 cm)...
  24. ncbi request reprint Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer
    R G Uzzo
    The Department of Urology, Fox Chase Cancer Centre, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    BJU Int 93:955-60. 2004
    ....
  25. ncbi request reprint Prostate cancer gene therapy and the role of radiation
    J M Kaminski
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burolme Avenue, Philadelphia, PA 19111, USA
    Cancer Treat Rev 28:49-64. 2002
    ..With further technological advances in radiation therapy, gene therapy, and the understanding of prostate cancer biology, gene therapy will potentially have an important role in prostate cancer therapy...
  26. doi request reprint Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of age
    Michael Diefenbach
    Urology and Oncological Sciences, Mount Sinai School of Medicine, New York, NY10029 6574, USA
    Psychol Health Med 13:146-61. 2008
    ..Among older patients (>68 years old, n = 192), lower levels of distress were associated with higher levels of functional QOL, and longer expected survival time was associated with better functional and physical QOL...
  27. ncbi request reprint Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10
    Javier F Torres-Roca
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Urology 69:505-9. 2007
    ....
  28. ncbi request reprint The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1082-7. 2007
    ..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
  29. pmc Radiation dose and late failures in prostate cancer
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 67:1074-81. 2007
    ..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
  30. ncbi request reprint Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 66:408-15. 2006
    ....
  31. ncbi request reprint Target localization for post-prostatectomy patients using CT and ultrasound image guidance
    Kamen Paskalev
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 6:40-9. 2005
    ..However, ultrasound alignments performed without the use of a template deteriorated patient positioning for two out of three patients, demonstrating that the use of a CT template was beneficial even at small initial displacements...
  32. ncbi request reprint Parameters for treatment decisions for salvage radiation therapy
    Shelly Bowers Hayes
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 23:8204-11. 2005
    ..These factors should be used as a guide to the options of local therapy alone (RT), local therapy plus systemic therapy (typically androgen deprivation therapy), and systemic therapy alone...
  33. ncbi request reprint Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Nat Clin Pract Oncol 2:12-3. 2005
  34. pmc Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  35. ncbi request reprint Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
    ..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
  36. pmc What dose of external-beam radiation is high enough for prostate cancer?
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:682-9. 2007
    ..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
  37. ncbi request reprint Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy
    Mary Feng
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 68:1417-23. 2007
    ..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
  38. ncbi request reprint Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 69:79-87. 2007
    ..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...
  39. pmc A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 71:338-45. 2008
    ..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
  40. pmc How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 70:1487-91. 2008
    ..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
  41. ncbi request reprint The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 112:55-60. 2008
    ..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
  42. ncbi request reprint Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 70:67-74. 2008
    ..To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer...
  43. ncbi request reprint Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation
    Steven J Feigenberg
    Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 8:2268. 2007
    ..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system...
  44. pmc Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202
    Mingxin Che
    Department of Pathology, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Int J Radiat Oncol Biol Phys 69:1117-23. 2007
    ....
  45. pmc Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo
    Radka Stoyanova
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:1151-60. 2007
    ..To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model...
  46. pmc Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202
    Arnab Chakravarti
    Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
    J Clin Oncol 25:3082-9. 2007
    ..In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202...
  47. pmc Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02
    Li Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 13:3585-90. 2007
    ..A follow-up investigation was carried out here in more contemporary high-risk men treated on Radiation Therapy Oncology Group 92-02 with STAD+RT or long-term AD+RT (LTAD+RT)...
  48. ncbi request reprint Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs
    Lili Chen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:903-11. 2007
    ....
  49. pmc Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
    ..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
  50. pmc Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    J Clin Oncol 25:2035-41. 2007
    ..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence...
  51. ncbi request reprint Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005
    ..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
  52. ncbi request reprint Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 62:397-405. 2005
    ..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
  53. ncbi request reprint Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1291-8. 2005
    ..The temporal kinetics of posttreatment PSA levels was examined to define the error in the classification of BF...
  54. ncbi request reprint Hazards of dose escalation in prostate cancer radiotherapy
    Deborah Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:1260-8. 2003
    ..To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications...
  55. ncbi request reprint Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study
    Darren J Little
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Urology 62:707-13. 2003
    ..To assess patient-reported prostate cancer-specific quality of life 2 and 3 years after radiotherapy to the prostate in a randomized dose-escalation trial of 70 versus 78 Gy conducted from 1993 to 1998...
  56. ncbi request reprint A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate
    Robert A Price
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:843-52. 2003
    ..The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery...
  57. ncbi request reprint Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy
    Didier Cowen
    Department of Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1148-54. 2002
    ..To determine the significance of Ki-67/MIB1 staining as a marker of patient outcome for prostate cancer patients treated with radiotherapy...
  58. ncbi request reprint Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
    Khanh H Nguyen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:377-83. 2003
    ....
  59. ncbi request reprint Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II
    Jeff M Michalski
    Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 56:192-8. 2003
    ..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406...
  60. ncbi request reprint Treatment of prostate cancer with regional lymph node (N1) metastasis
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 13:121-9. 2003
    ..Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP...
  61. ncbi request reprint Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate
    Charles J Rosser
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 169:2160-5. 2003
    ..We determined the likelihood of biochemical failure in those free of disease 5 years after radiotherapy and identified those at risk for early versus late biochemical failure...
  62. ncbi request reprint Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 169:2153-7; discussion 2157-9. 2003
    ..We evaluated the impact of backdating on no biochemical evidence of disease (bNED) control and suggest changes in the definition...
  63. ncbi request reprint A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer
    Alan Pollack
    J Clin Oncol 21:1899-901. 2003
  64. ncbi request reprint Is intraoperative nomogram-based overplanning of prostate implants necessary?
    WARREN D D'SOUZA
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 56:462-7. 2003
    ..Several investigators have described intraoperative planning of prostate implants based on a nomogram. The aim of this work was to investigate the adequacy of the nomogram in predicting the total activity necessary for optimal dosimetry...
  65. ncbi request reprint Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer
    Deborah Watkins Bruner
    Department of Population Science, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 58:34-42. 2004
    ..To assess the preferences and utilities for prostate cancer health state scenarios of men treated with three-dimensional conformal radiotherapy and the predictors of treatment preferences...
  66. ncbi request reprint Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:43-52. 2004
    ....
  67. ncbi request reprint What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:1003-10. 2005
    ..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
  68. ncbi request reprint Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:695-701. 2005
    ..To determine whether the radiation dose is a determinant of clinical outcome in patients with a lymph node risk of >15% treated using whole pelvic (WP), partial pelvic (PP), or prostate only (PO) fields...
  69. ncbi request reprint Androgen suppression plus radiation therapy for prostate cancer
    Eric M Horwitz
    JAMA 292:2084-5; author reply 2085. 2004
  70. ncbi request reprint MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT
    Lili Chen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 60:636-47. 2004
    ..Furthermore, it will reduce treatment cost by avoiding redundant CT scans and save patient, staff, and machine time. The purpose of this study is to investigate the dosimetric accuracy of MRI-based treatment planning for prostate IMRT...
  71. ncbi request reprint The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
    ....
  72. ncbi request reprint Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  73. ncbi request reprint A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 59:380-5. 2004
    ..Two models for stratification of prostate cancer aggressiveness predominate for the purposes of daily treatment decision making. This study investigates the relationships between these two clinically popular models...
  74. ncbi request reprint Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:634-9. 2002
    ..To investigate whether low partial pressure of oxygen (PO2) in prostate cancer (CaP) predicts for biochemical outcome after radiotherapy. We previously reported that hypoxic regions exist in human CaP...
  75. ncbi request reprint Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer
    Charles J Rosser
    Department of Urology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    J Urol 168:2001-5. 2002
    ..We characterize the prostate-specific antigen (PSA) bounce in patients who underwent external beam radiation therapy for prostate cancer and correlate the PSA bounce with the development of biochemical disease progression...
  76. ncbi request reprint Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 54:1314-21. 2002
    ..To identify dosimetric, anatomic, and clinical factors that correlate with late rectal toxicity after three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer...
  77. ncbi request reprint The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 100:538-43. 2004
    ..However, there is little direct evidence that dose escalation has an impact on distant metastasis (DM) or overall mortality (OM). These associations were examined in the current study...
  78. ncbi request reprint Experience of ultrasound-based daily prostate localization
    Anurag Chandra
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 56:436-47. 2003
    ....

Research Grants1

  1. Xenogen IVIS-200 Bioluminescent Imaging System
    Alan Pollack; Fiscal Year: 2007
    ..The information gained will guide researchers in the appropriate use of the therapeutic or preventive agents being studied, and elucidate the roles of specific molecular events in tumor formation and development. ..